The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson's Disease.

Directional leads Parkinson’s disease clinical programming clinical refinement functional mapping timesaving

Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
30 Dec 2023
Historique:
medline: 8 1 2024
pubmed: 8 1 2024
entrez: 8 1 2024
Statut: aheadofprint

Résumé

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a preferred treatment for parkinsonian patients with severe motor fluctuations. Proper targeting of the STN sensorimotor segment appears to be a crucial factor for success of the procedure. The recent introduction of directional leads theoretically increases stimulation specificity in this challenging area but also requires more precise stimulation parameters. We investigated whether commercially available software for image guided programming (IGP) could maximize the benefits of DBS by informing the clinical standard care (CSC) and improving programming workflows. We prospectively analyzed 32 consecutive parkinsonian patients implanted with bilateral directional leads in the STN. Double blind stimulation parameters determined by CSC and IGP were assessed and compared at three months post-surgery. IGP was used to adjust stimulation parameters if further clinical refinement was required. Overall clinical efficacy was evaluated one-year post-surgery. We observed 78% concordance between the two electrode levels selected by the blinded IGP prediction and CSC assessments. In 64% of cases requiring refinement, IGP improved clinical efficacy or reduced mild side effects, predominantly by facilitating the use of directional stimulation (93% of refinements). The use of image guided programming saves time and assists clinical refinement, which may be beneficial to the clinical standard care for STN-DBS and further improve the outcomes of DBS for PD patients.

Sections du résumé

BACKGROUND BACKGROUND
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a preferred treatment for parkinsonian patients with severe motor fluctuations. Proper targeting of the STN sensorimotor segment appears to be a crucial factor for success of the procedure. The recent introduction of directional leads theoretically increases stimulation specificity in this challenging area but also requires more precise stimulation parameters.
OBJECTIVE OBJECTIVE
We investigated whether commercially available software for image guided programming (IGP) could maximize the benefits of DBS by informing the clinical standard care (CSC) and improving programming workflows.
METHODS METHODS
We prospectively analyzed 32 consecutive parkinsonian patients implanted with bilateral directional leads in the STN. Double blind stimulation parameters determined by CSC and IGP were assessed and compared at three months post-surgery. IGP was used to adjust stimulation parameters if further clinical refinement was required. Overall clinical efficacy was evaluated one-year post-surgery.
RESULTS RESULTS
We observed 78% concordance between the two electrode levels selected by the blinded IGP prediction and CSC assessments. In 64% of cases requiring refinement, IGP improved clinical efficacy or reduced mild side effects, predominantly by facilitating the use of directional stimulation (93% of refinements).
CONCLUSIONS CONCLUSIONS
The use of image guided programming saves time and assists clinical refinement, which may be beneficial to the clinical standard care for STN-DBS and further improve the outcomes of DBS for PD patients.

Identifiants

pubmed: 38189764
pii: JPD225126
doi: 10.3233/JPD-225126
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Anne-Sophie Rolland (AS)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Medical Pharmacology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Gustavo Touzet (G)

CHU Lille, Department of Neurosurgery, LICEND COEN Center, Lille, France.

Nicolas Carriere (N)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Eugenie Mutez (E)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Alexandre Kreisler (A)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Clemence Simonin (C)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Gregory Kuchcinski (G)

CHU Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neuroradiology, LICEND COEN Center, Lille, France.

Najib Chalhoub (N)

Diagnostic and interventional neuroradiology, Lille University Hospital, Lille, France.

Jean-Pierre Pruvo (JP)

Diagnostic and interventional neuroradiology, Lille University Hospital, Lille, France.

Luc Defebvre (L)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Nicolas Reyns (N)

CHU Lille, Department of Neurosurgery, LICEND COEN Center, Lille, France.

David Devos (D)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Medical Pharmacology, LICEND COEN Center, I-SITE ULNE, Lille, France.
University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Caroline Moreau (C)

University Lille, Lille Neuroscience & Cognition, INSERM UMR_S1172, CHU Lille, Department of Neurology, LICEND COEN Center, I-SITE ULNE, Lille, France.

Classifications MeSH